Ingenuity Systems Announces Multi-Year Deal With Bristol-Myers Squibb for IPA

REDWOOD CITY, Calif., Sept. 2 /PRNewswire/ -- Ingenuity Systems, the
leading provider of information solutions for life science researchers, today
announced a multi-year agreement with Bristol-Myers Squibb Company (NYSE: BMY)
for use of the Ingenuity Pathways Analysis (IPA) software application.
Bristol-Myers Squibb will continue to leverage IPA for the interpretation,
modeling, and visualization of genomics and proteomics data to identify key
biological insights to accelerate their drug discovery programs.
The agreement provides enterprise-wide access to IPA for Bristol-Myers
Squibb research scientists. Research teams have access to the newest version
of IPA, which supports Affymetrix GeneChip(R) Exon Arrays, supports many new
species, and includes recent enhancements such as the Path Designer publishing
tool and capabilities for metabolomics, biomarker, and toxicology research.
The all-in-one nature of IPA ensures easy workflows for maximum efficiency
across Bristol-Meyers Squibb's global organization.
"We are very pleased that Bristol-Myers Squibb has chosen Ingenuity as a
partner for its drug discovery and development programs," commented Sean
Scott, SVP Commercial Operations, Ingenuity Systems. "Bristol-Myers Squibb has
been a highly valued customer since 2004 and we regard their license renewal
and multi-year commitment as confirmation that IPA is an integral part of
their discovery programs."
About Ingenuity Pathways Analysis
Ingenuity Pathways Analysis is an all-in-one software application that
enables researchers to model, analyze, and understand the complex biological
and chemical systems at the core of life science research. IPA's search
capabilities provide users with access to the highest quality detail-rich
knowledge available on genes, drugs, chemicals, protein families, cellular and
disease processes, and signaling and metabolic pathways. IPA supports analysis
of data from all experimental platforms, and is used at all stages of the drug
discovery and development process, including target identification and
validation, biomarker discovery, molecular toxicology, metabolomics, and
pharmacogenomics. IPA has been broadly adopted and cited in hundreds of
peer-reviewed journals.
About Ingenuity Systems(R)
Ingenuity Systems is a leading provider of information solutions and
custom services for life science researchers, computational biologists and
bioinformaticists, and life science industry suppliers. Our long-term focus on
innovation in semantic search has allowed us to create groundbreaking
technologies that have one common goal -- to generate maximum value from all
types of biological and chemical knowledge. Ingenuity offerings leverage the
Ingenuity Knowledge Base, which contains uniquely structured literature
findings that allow scientists to ask complex biological questions and gain
rapid insight into their experimental data or systems of interest. Today,
Ingenuity's solutions are used by thousands of researchers at hundreds of
leading pharmaceutical, biotechnology, academic, and government research
institutions worldwide. http://www.ingenuity.com
SOURCE Ingenuity Systems

Heidi Bullock, Director, Marketing of Ingenuity Systems, +1-650-381-5150